BUSINESS Business Summary We are a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin, which we believe is anext-generation anthracycline and, with it, are conducting a pivotal Phase 3 trial in combination with cytarabine for the treatment of subjects with relapsed/refractory (R/R) acute myeloid leukemia (AML). We call this the MIRACLE trial (derived from Moleculin R/R AML AnnAraC Clinical Evaluation).A bli...
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-18 | 2025-12-31 | 0001437749-26-008841 | EDGAR | 92K words |
| 2025-03-21 | 2024-12-31 | 0001437749-25-008751 | EDGAR | — |
| 2024-03-22 | 2023-12-31 | 0001437749-24-009044 | EDGAR | — |
| 2023-03-22 | 2022-12-31 | 0001437749-23-007537 | EDGAR | — |
| 2022-03-24 | 2021-12-31 | 0001437749-22-007103 | EDGAR | — |
| 2021-03-24 | 2020-12-31 | 0001437749-21-006940 | EDGAR | — |
| 2020-03-19 | 2019-12-31 | 0001659617-20-000066 | EDGAR | — |
| 2019-02-21 | 2018-12-31 | 0001659617-19-000018 | EDGAR | — |
| 2018-03-28 | 2017-12-31 | 0001659617-18-000027 | EDGAR | — |
| 2017-04-03 | 2016-12-31 | 0001144204-17-018352 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001437749-25-034839 | EDGAR | 27K words |
| 2025-08-12 | 2025-06-30 | 0001437749-25-026225 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0001437749-25-016466 | EDGAR | — |
| 2024-11-08 | 2024-09-30 | 0001437749-24-034236 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001437749-24-026367 | EDGAR | — |
| 2024-05-10 | 2024-03-31 | 0001437749-24-016031 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001437749-23-031391 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001437749-23-023021 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0001437749-23-013582 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001437749-22-026888 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001437749-22-020389 | EDGAR | — |
| 2022-05-11 | 2022-03-31 | 0001437749-22-011925 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-03 | 0001437749-26-025474 | EDGAR | — |
| 2026-07-31 | 0001437749-26-025167 | EDGAR | — |
| 2026-03-23 | 0001437749-26-009298 | EDGAR | 1K words |
| 2026-03-19 | 0001437749-26-008951 | EDGAR | — |
| 2026-03-19 | 0001437749-26-008949 | EDGAR | — |
| 2026-02-20 | 0001437749-26-004800 | EDGAR | — |
| 2026-02-18 | 0001437749-26-004558 | EDGAR | — |
| 2026-02-18 | 0001437749-26-004455 | EDGAR | — |
| 2026-02-17 | 0001437749-26-004236 | EDGAR | — |
| 2026-02-05 | 0001437749-26-003119 | EDGAR | — |
497 total filings indexed. 465 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001659617 |
| Ticker | MBRX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.moleculin.com |
| Listed | 2016-06-02 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/MBRX (~200 tokens, structured JSON with cryptographic provenance)